# Nasogastric and intravenous erythromycin as prokinetic in intensive care patients: a randomised controlled study

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>
12/09/2003	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
12/09/2003	Completed	Results
Last Edited	Condition category	Individual participant data
31/03/2020	Signs and Symptoms	<ul><li>Record updated in last year</li></ul>

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr A Guha

#### Contact details

Anaesthesia
University Hospital Aintree
Longmoor Lane
Fazakerley
Liverpool
United Kingdom
L9 7AL
+44 (0)151 529 5152 / 5153
abc@email.com

# Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

## Secondary identifying numbers

N0025107242

# Study information

#### Scientific Title

Nasogastric and intravenous erythromycin as prokinetic in intensive care patients: a randomised controlled study

#### **Study objectives**

Erythromycin's effect on gastric emptying in intensive care

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomised controlled trial

## Primary study design

Interventional

#### Secondary study design

Randomised controlled trial

#### Study setting(s)

Hospital

#### Study type(s)

Treatment

#### Participant information sheet

#### Health condition(s) or problem(s) studied

Signs and Symptoms: Gastric emptying

#### **Interventions**

A 5 ml sample of blood will be taken for measuring baseline paracetamol content. 1.5 g of soluble paracetamol will be administered to them through their nasogastric tube. They will then be randomised to receive 250 g of either nasogastric or intravenous erythromycin. Further blood samples (5 ml each time) will be taken at 15, 30, 45, 60, 120, 180 and 240 min after giving paracetamol. These samples will then be sent to the laboratory for assay. After obtaining the data, these will be analysed for statistical significance.

#### Intervention Type

Drug

#### **Phase**

#### Not Applicable

# Drug/device/biological/vaccine name(s)

Erythromycin

## Primary outcome measure

Not provided at time of registration

## Secondary outcome measures

Not provided at time of registration

#### Overall study start date

01/01/2002

#### Completion date

01/07/2003

# Eligibility

#### Key inclusion criteria

Intensive Care patients who will be recruited into the study if they exhibit a failure to absorb nasogastric feed.

#### Participant type(s)

**Patient** 

#### Age group

**Not Specified** 

#### Sex

**Not Specified** 

#### Target number of participants

Not provided at time of registration

#### Key exclusion criteria

Not provided at time of registration

#### Date of first enrolment

01/01/2002

#### Date of final enrolment

01/07/2003

# Locations

#### Countries of recruitment

England

**United Kingdom** 

## Study participating centre University Hospital Aintree Liverpool United Kingdom L9 7AL

# Sponsor information

#### Organisation

Department of Health (UK)

# Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

## Sponsor type

Government

#### Website

http://www.doh.gov.uk

# Funder(s)

# Funder type

Hospital/treatment centre

#### **Funder Name**

Aintree Hospitals NHS Trust (UK)

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

# Individual participant data (IPD) sharing plan

**IPD sharing plan summary**Not provided at time of registration